Edwards Lifesciences | EW - Gross Profit On Sales

Stock Price
82.28
Daily Change
-1.18 -1.41%
Monthly
3.50%
Yearly
7.87%
Q2 Forecast
82.35

Edwards Lifesciences reported $1.29B in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Abbott USD 5.86B 675M Mar/2026
Artivion USD 73.14M 1.25M Dec/2025
AtriCure USD 105.34M 4M Dec/2025
Baxter International USD 577M 373M Dec/2025
Becton, Dickinson and Co. USD 2.41B 1.72B Dec/2025
Boston Scientific USD 3.61B 64M Mar/2026
Cooper Companies USD 695.2M 44.4M Dec/2025
Dexcom USD 792.7M 61.3M Dec/2025
Edwards Lifesciences USD 1.29B 59.4M Mar/2026
Globus Medical USD 535.95M 49.28M Dec/2025
ICU Medical USD 202.98M 2.1M Dec/2025
Inogen USD 41.34M 1.39M Sep/2024
Insulet USD 568.6M 58.5M Dec/2025
Integra LifeSciences USD 217.1M 10.11M Dec/2025
Intuitive Surgical USD 1.83B 73.8M Mar/2026
J&J USD 17.24B 642M Mar/2026
Masimo USD 247.3M 16.7M Dec/2025
Medtronic USD 5.41B 27M Dec/2025
Merit Medical Systems USD 195.35M 8.94M Dec/2025
Stryker USD 4.49B 633M Dec/2025
Tandem Diabetes Care USD 167.46M 33.17M Dec/2025
Teleflex USD 307.45M 144.2M Dec/2025
Zimmer Biomet Holdings USD 1.27B 8.1M Dec/2025